Interaction Checker

İkosapent etil etkileşimleri

omega-3 yağ asidi sınıfından İkosapent etil (Vascepa) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 33 belgelenmiş etkileşim var: 0 majör, 33 orta, 0 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Orta düzey etkileşimler (33)

  • Amlodipin ve atorvastatindihidropiridin kalsiyum kanal blokeriOrta

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

  • ApiksabanantikoagülanOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • ArgatrobanantikoagülanOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • AspirinNSAİİOrta

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (İkosapent etil etiketi, Uyarılar ve önlemler)

  • Aspirin ve dipiridamolantitrombosit ilaçOrta

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (İkosapent etil etiketi, Uyarılar ve önlemler)

  • AtorvastatinstatinOrta

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

  • Balık yağı (omega-3)Bitkisel ürün ve takviyeOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • BivalirudinantikoagülanOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • Butalbital, aspirin ve kafeinbarbitüratOrta

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (İkosapent etil etiketi, Uyarılar ve önlemler)

  • Butalbital, aspirin, kafein ve kodeinbarbitüratOrta

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (İkosapent etil etiketi, Uyarılar ve önlemler)

  • DabigatranantikoagülanOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • Dipiridamolantitrombosit ilaçOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • EdoksabanantikoagülanOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • EnoksaparinantikoagülanOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • Eptifibatidantitrombosit ilaçOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • Ezetimib ve simvastatinstatinOrta

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

  • FluvastatinstatinOrta

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

  • FondaparinuksantikoagülanOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • HeparinantikoagülanOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • Kangrelorantitrombosit ilaçOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • Klopidogrelantitrombosit ilaçOrta

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (İkosapent etil etiketi, Uyarılar ve önlemler)

  • LovastatinstatinOrta

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

  • Orfenadrin, aspirin ve kafeinkas gevşeticiOrta

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (İkosapent etil etiketi, Uyarılar ve önlemler)

  • PitavastatinstatinOrta

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

  • Prasugrelantitrombosit ilaçOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • PravastatinstatinOrta

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

  • RivaroksabanantikoagülanOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • RosuvastatinstatinOrta

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

  • Silostazolantitrombosit ilaçOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • SimvastatinstatinOrta

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

  • Tikagrelorantitrombosit ilaçOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • Tirofibanantitrombosit ilaçOrta

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (İkosapent etil etiketi, İlaç etkileşimleri)

  • VarfarinantikoagülanOrta

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (İkosapent etil etiketi, Uyarılar ve önlemler)

Kullandığınız her şeyi İkosapent etil ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.